Incannex Healthcare IncNASDAQ:IXHL
- LAST PRICE2.3800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.2600/ 70
- Ask / Lots2.5200/ 4
- Open / Previous Close2.4000 / 2.3800
- Day Range
- 52 Week Range
- Volume14,374
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IXHL |
|---|---|---|
| 09:32 ET | 3406 | 2.39 |
| 09:36 ET | 747 | 2.4 |
| 09:38 ET | 600 | 2.39 |
| 09:41 ET | 250 | 2.39 |
| 09:57 ET | 100 | 2.415 |
| 10:12 ET | 1181 | 2.4 |
| 11:22 ET | 100 | 2.41 |
| 01:51 ET | 1500 | 2.44 |
| 02:13 ET | 200 | 2.38 |
| 02:29 ET | 300 | 2.3799 |
| 03:00 ET | 100 | 2.37 |
| 03:03 ET | 1657 | 2.375 |
| 03:41 ET | 443 | 2.38 |
Apr 16, 2024
Incannex Healthcare Inc. Quarterly Update, Q1 2024, from 8:00AM ET on Tuesday Apr 16, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Incannex Healthcare Inc | 37.8M | -6.3x | --- |
TherapeuticsMD Inc | 21.8M | -2.5x | --- |
Talphera Inc | 17.6M | -1.4x | --- |
Allied Corp | 16.5M | -1.6x | --- |
Cocrystal Pharma Inc | 15.2M | -0.8x | --- |
Sentient Brands Holdings Inc | 5.5M | -12.1x | --- |
Company Information
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
Contact Information
- Headquarters
- 18 East 50th Street, 5th FloorNEW YORK, NY, United States 10022
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Troy Valentine
- President, Chief Executive Officer, Executive Director
- Joel Latham
- Chief Financial Officer, Controller, Treasurer, Company Secretary
- Joseph Swan
- Chief Technology Officer
- Lekhram Changoer
- Non-Executive Director
- George Anastassov
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $37.8M |
|---|---|
Revenue (TTM) | $163.4K |
Shares Outstanding | 15.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.38 |
Book Value | $0.04 |
P/E Ratio | -6.3x |
Price/Sales (TTM) | 231.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,614.10% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
